<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.340">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>pituitary-diseases</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
  vertical-align: middle;
}
</style>


<script src="pituitary-diseases_files/libs/clipboard/clipboard.min.js"></script>
<script src="pituitary-diseases_files/libs/quarto-html/quarto.js"></script>
<script src="pituitary-diseases_files/libs/quarto-html/popper.min.js"></script>
<script src="pituitary-diseases_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="pituitary-diseases_files/libs/quarto-html/anchor.min.js"></script>
<link href="pituitary-diseases_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="pituitary-diseases_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="pituitary-diseases_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="pituitary-diseases_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="pituitary-diseases_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">



<section id="harvey-williams-cushing" class="level1">
<h1>Harvey Williams Cushing</h1>
<p><img src="img%5CPituitary-Diseases0.jpg" class="img-fluid"></p>
<p><strong>first anaesthetic chart</strong></p>
<p><strong>clinical use of X-rays</strong></p>
<p><strong>relationship between systolic blood pressure and cranial pressure</strong></p>
<p><strong>application of electrical coagulation to neurosurgery</strong></p>
<p><strong>https://en.wikipedia.org/wiki/Harvey_Cushing</strong></p>
<p><img src="img%5CPituitary-Diseases1.png" class="img-fluid"></p>
<p><strong>http://www.whonamedit.com/doctor.cfm/980.html</strong></p>
<p><img src="img%5CPituitary-Diseases2.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases3.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases4.png" class="img-fluid"></p>
<p><strong>Ann R Coll Surg Engl. 1969 Apr;44(4):180-1.</strong></p>
<p><img src="img%5CPituitary-Diseases5.png" class="img-fluid"></p>
<p><strong>Ann Surg. 1909 Dec;50(6):1002-17.</strong></p>
<p><img src="img%5CPituitary-Diseases6.png" class="img-fluid"></p>
<p><strong>Ann Surg. 1909 Dec;50(6):1002-17.</strong></p>
<p><img src="img%5CPituitary-Diseases7.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases8.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases9.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases10.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases11.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases12.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases13.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases14.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
<p><img src="img%5CPituitary-Diseases15.png" class="img-fluid"></p>
<p><strong>Pituitary. 2010 Dec;13(4):324-8.</strong></p>
</section>
<section id="davutun-golyatı-öldürmesi-i.samuel" class="level1">
<h1>Davut’un Golyat’ı Öldürmesi (I.Samuel)</h1>
<p><strong>1.Sa.17: 4 Filist ordugahından Gatlı Golyat adında usta bir dövüşçüortaya çıktı. </strong> <strong>Boyu </strong> <strong>altı arşın bir karıştı*fe*.D Not 17:4 “Altı arşın bir karış”: </strong> <strong>Yaklaşık 2.9 m</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 5 Başına tunç* miğfer takmış, pullu bir zırh kuşanmıştı. </strong> <strong>Tunç zırhın ağırlığı</strong> __ beş bin şekeldi*ff*.D Not 17:5 “Beş bin şekel”: __ <strong>Yaklaşık 57.5 kg</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 6 Baldırları zırhlarla korunmuştu. Omuzları arasında tunç bir pala asılıydı.</strong></p>
<p><strong>1.Sa.17: 7 Mızrağının sapı dokumacı tezgahının sırığı gibiydi. </strong> <strong>Mızrağındemir başının ağırlığı</strong> __ altı yüz şekeldi*fg*. Golyat’ın önüsıra kalkanını taşıyan bir adam yürüyordu.D Not 17:7 “Altı yüz şekel”: __ <strong>Yaklaşık 6.9 kg</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 8 Golyat durup İsrail ordusuna, “Neden savaş düzeni aldınız?” diye haykırdı, “Ben Filistli’yim, sizse Saul’un kölelerisiniz. Aranızdan karşıma çıkacak birini seçin.</strong></p>
<p><strong>1.Sa.17: 38 Sonra kendi giysilerini Davut’a verdi; başına tunç miğfer taktı, ona bir zırh giydirdi.</strong></p>
<p><strong>1.Sa.17: 39 Davut giysilerinin üzerine kılıcını kuşanıp yürümeye çalıştı. Çünkü bu giysilere alışık değildi. Saul’a, “Bunlarla yürüyemiyorum” dedi, “Çünkü alışık değilim.” Sonra giysileri üzerinden çıkardı.</strong></p>
<p><strong>1.Sa.17: 40 Değneğini alıp dereden beş çakıl taşı seçti. Bunları çoban dağarcığının cebine koyduktan sonra </strong> <strong>sapanını alıp Filistli Golyat’a doğru ilerledi</strong> <strong>.</strong></p>
<p><strong>1.Sa.17: 48 Golyat saldırmak amacıyla Davut’a doğru ilerledi. Davut daonunla dövüşmek üzere hemen Filist cephesine doğru koştu.</strong></p>
<p><strong>1.Sa.17: 49 </strong> <strong>Elini dağarcığına sokup bir taş çıkardı, sapanla fırlattı.Taş Filistli’nin alnına çarpıp saplandı. Filistli yüzükoyun yere düştü.</strong></p>
<p><strong>1.Sa.17: 50 Böylece Davut Filistli Golyat’ı sapan ve taşla yendi.Elinde kılıç olmaksızın onu yere serdi.</strong></p>
<p><strong>1.Sa.17: 51 Sonra koşup üzerine çıktı. Golyat’ın kılıcını tutupkınından çektiği gibi onu öldürdü ve başını kesti.Kahraman Golyat’ın öldüğünü gören Filistliler kaçtılar.</strong></p>
<p><strong>Pierre Puget ‘David, vainqueur de Goliath’ </strong></p>
<p><em>A History of Acromegaly </em> <strong>Pituitary 1999;2:7–28</strong></p>
<p><img src="img%5CPituitary-Diseases16.jpg" class="img-fluid"></p>
<p><strong>Undoubtedly Goliath’s great size was due to </strong> <strong>acromegaly </strong> <strong>secondary to a pituitary macroadenoma. This pituitary adenoma was apparently large enough to induce </strong> <strong>visual field deficits</strong> __ by its pressure on the optic chiasm, which made Goliath __ <strong>unable to follow the young David </strong> <strong>as he circled him. The </strong> <strong>stone entered Goliath’s cranial vault </strong> <strong>through a </strong> <strong>markedly thinned frontal bone</strong> <strong>, which resulted from enlargement of the frontal paranasal sinus, a frequent feature of acromegaly. The stone lodged in Goliath’s enlarged pituitary and caused a </strong> <strong>pituitary hemorrhage</strong> <strong>, resulting in </strong> <strong>transtentorial herniation and death</strong> <strong>.</strong></p>
<p><strong>Radiology. 1990 Jul;176(1):288. </strong></p>
<p><img src="img%5CPituitary-Diseases17.jpg" class="img-fluid"></p>
</section>
<section id="pituitary-diseases" class="level1">
<h1>Pituitary Diseases</h1>
</section>
<section id="serdar-balci-md" class="level1">
<h1>Serdar BALCI, MD</h1>
</section>
<section id="pituitary-gland" class="level1">
<h1>Pituitary gland</h1>
<ul>
<li><strong>small, bean-shaped </strong></li>
<li><strong>lies at the base of the brain within the sella turcica</strong></li>
<li><strong>Related to the hypothalamus</strong>
<ul>
<li><strong>stalk, composed of axons</strong></li>
<li><strong>venous plexus</strong></li>
</ul></li>
<li><strong>Anterior lobe (adenohypophysis)</strong></li>
<li><strong>Posterior lobe (neurohypophysis)</strong></li>
</ul>
</section>
<section id="anterior-pituitary-adenohypophysis" class="level1">
<h1>Anterior pituitary (adenohypophysis)</h1>
<ul>
<li><strong>Epithelial cells</strong></li>
<li><strong>Embryologically from the developing oral cavity</strong></li>
<li><strong>Normal histology:</strong>
<ul>
<li><strong>Cells containing basophilic cytoplasm</strong></li>
<li><strong>Eosinophilic cytoplasm</strong></li>
<li><strong>Poorly staining ( chromophobic ) cytoplasm</strong></li>
</ul></li>
</ul>
<p><img src="img%5CPituitary-Diseases18.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPituitary-Diseases19.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPituitary-Diseases20.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases21.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases22.jpg" class="img-fluid"></p>
</section>
<section id="pituitary-diseases-1" class="level1">
<h1>Pituitary Diseases</h1>
<ul>
<li><strong>Hyperpituitarism</strong>
<ul>
<li><strong>excessive secretion of trophic hormones</strong></li>
<li><strong>Anterior pituitary adenoma</strong></li>
</ul></li>
<li><strong>Hypopituitarism</strong>
<ul>
<li><p><strong>Deficiency of trophic hormones</strong></p></li>
<li><p><strong>Ischemic injury, surgery or radiation, and inflammatory reactions</strong></p></li>
<li><p><strong>Nonfunctional pituitary adenomas destruct normal structures</strong></p></li>
<li><p><strong>Local mass effects</strong></p></li>
<li><p><strong>Sellar expansion, bony erosion, and disruption of the diaphragma sellae</strong></p></li>
<li><p><strong>Compress decussating fibers in the optic chiasm</strong></p>
<ul>
<li><strong>lateral (temporal) visual fields, bitemporal hemianopsia</strong></li>
</ul></li>
<li><p><strong>Elevated intracranial pressure</strong></p>
<ul>
<li><strong>headache, nausea, and vomiting</strong></li>
</ul></li>
<li><p><strong>Extend into the base of the brain</strong></p>
<ul>
<li><strong>invasive pituitary adenoma</strong></li>
<li><strong>seizures or obstructive hydrocephalus</strong></li>
<li><strong>cranial nerve palsy</strong></li>
</ul></li>
<li><p><strong>Acute hemorrhage into an adenoma</strong></p>
<ul>
<li><strong>rapid enlargement of the lesion</strong></li>
<li><strong>pituitary apoplexy</strong></li>
<li><strong>rapidly fatal</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="hyperpituitarism" class="level1">
<h1>Hyperpituitarism</h1>
<ul>
<li><strong>The most common cause of hyperpituitarism is an adenoma arising in the anterior lobe</strong></li>
<li><strong>Less common causes</strong>
<ul>
<li><strong>Hyperplasia</strong></li>
<li><strong>carcinomas of the anterior pituitary</strong></li>
<li><strong>secretion of hormones by some extrapituitary tumors</strong></li>
<li><strong>Certain hypothalamic disorders</strong></li>
</ul></li>
</ul>
</section>
<section id="pathogenesis-of-pituitary-adenomas" class="level1">
<h1>Pathogenesis of Pituitary Adenomas</h1>
<ul>
<li><strong>Guanine nucleotide–binding protein (G protein) mutations</strong></li>
<li><strong>critical role in signal transduction</strong>
<ul>
<li><strong>from cell surface receptors (e.g., growth hormone–releasing hormone receptor) to intracellular effectors (e.g., adenyl cyclase)</strong>
<ul>
<li><strong>generate second messengers (e.g., cAMP).</strong></li>
</ul></li>
<li><strong>encoded by the GNAS1 gene</strong></li>
</ul></li>
<li><strong>40% of growth hormone–secreting somatotroph cell adenomas and a minority of adrenocorticotropic hormone (ACTH)–secreting corticotroph cell adenomas have GNAS1 mutations</strong></li>
</ul>
<p><img src="img%5CPituitary-Diseases23.png" class="img-fluid"></p>
<ul>
<li><strong>Familial pituitary adenomas</strong>
<ul>
<li><strong>MEN1, CDKN1B, PRKAR1A, and AIP</strong></li>
<li><strong>Germline inactivating mutations of the MEN1 gene</strong>
<ul>
<li><strong>multiple endocrine neoplasia syndrome type 1 (MEN-1)</strong></li>
</ul></li>
<li><strong>CDKN1B gene</strong>
<ul>
<li><strong>cell cycle checkpoint regulator p27 or KIP1</strong></li>
</ul></li>
<li><strong>Germline mutations of CDKN1B</strong>
<ul>
<li><strong>“MEN-1 like” syndrome who lack MEN1 abnormalities</strong></li>
</ul></li>
<li><strong>Aryl hydrocarbon receptor–interacting protein (AIP)</strong>
<ul>
<li><strong>pituitary adenoma predisposition gene</strong></li>
<li><strong>GH-secreting adenomas at a younger age (before 35 years) than that typical for sporadic GH adenoma patients</strong></li>
</ul></li>
</ul></li>
<li><strong>Mutations of TP53</strong>
<ul>
<li><strong>associated with a propensity for aggressive behavior, such as invasion and recurrence</strong></li>
</ul></li>
</ul>
<p><img src="img%5CPituitary-Diseases24.png" class="img-fluid"></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
<p><img src="img%5CPituitary-Diseases25.png" class="img-fluid"></p>
<p><strong>Macroadenomas &gt;1 cm</strong></p>
<p><strong>Microadenomas &lt;1 cm</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPituitary-Diseases26.png" class="img-fluid"></p>
<p><strong>Pituitary adenoma is a well-circumscribed, soft lesion</strong></p>
<p><strong>Smaller tumors, be confined by the sella turcica</strong></p>
<p><strong>Larger lesions may compress the optic chiasm and adjacent structures</strong></p>
<p><strong>Erode the sella turcica and anterior clinoid processes</strong></p>
<p><strong>Extend locally into the cavernous and sphenoidal sinuses</strong></p>
<p><strong>30% of cases, nonencapsulated and infiltrate adjacent bone, dura, and (uncommonly) brain</strong></p>
<p><strong>Foci of hemorrhage and/or necrosis are common in larger adenomas</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPituitary-Diseases27.png" class="img-fluid"></p>
<p><strong>Massive, nonfunctioning adenoma has grown far beyond the confines of the sella turcica and has distorted the overlying brain</strong></p>
<p><strong>Nonfunctioning adenomas tend to be larger at the time of diagnosis than those that secrete a hormone</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img src="img%5CPituitary-Diseases28.png" class="img-fluid"></p>
<p><strong>Relatively uniform, polygonal cells arrayed in sheets, cords, or papillae</strong></p>
<p><strong>Supporting connective tissue, or reticulin, is sparse</strong></p>
<p><strong>Soft, gelatinous consistency</strong></p>
<p><strong>Nuclei of the neoplastic cells may be uniform or pleomorphic</strong></p>
<p><strong>Mitotic activity usually is scanty</strong></p>
<p><strong>Cytoplasm of the constituent cells may be acidophilic, basophilic, or chromophobic, depending on the type and amount of secretory product within the cell, but it is fairly uniform throughout the neoplasm</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>anterior pituitary parenchyma</strong></p>
<p><strong>pituitary adenoma</strong></p>
<p><img src="img%5CPituitary-Diseases29.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases30.png" class="img-fluid"></p>
<p><strong>Cellular monomorphism and the absence of a significant reticulin network distinguish pituitary adenomas from non-neoplastic anterior pituitary parenchyma</strong></p>
</section>
<section id="pituitary-adenomas" class="level1">
<h1>Pituitary Adenomas</h1>
<ul>
<li><strong>The functional status of the adenoma cannot be reliably predicted from its histologic appearance</strong></li>
<li><strong>Adenomas with TP53 mutations</strong>
<ul>
<li><strong>brisk mitotic activity</strong></li>
<li><strong>higher proliferation rates</strong></li>
<li><strong>Designated as “atypical adenomas”</strong></li>
<li><strong>potential for aggressive behavior</strong></li>
</ul></li>
<li><strong>Composed of a single cell type and produce a single predominant hormone</strong></li>
<li><strong>Some pituitary adenomas can secrete two different hormones</strong>
<ul>
<li><strong>growth hormone and prolactin most common combination</strong></li>
<li><strong>rarely plurihormonal</strong></li>
</ul></li>
<li><strong>Functional</strong>
<ul>
<li><strong>Associated with hormone excess and clinical manifestations</strong></li>
</ul></li>
<li><strong>Nonfunctioning adenomas</strong>
<ul>
<li><strong>Mass effects, hypopituitarism</strong></li>
<li><strong>Demonstration of hormone production at the tissue level only, without clinical manifestations of hormone excess</strong></li>
</ul></li>
<li><strong>Truly “hormone negative”</strong>
<ul>
<li><strong>Absence of immunohistochemical reactivity or ultrastructural evidence of hormone production</strong></li>
</ul></li>
<li><strong>Nonfunctioning and hormone-negative adenomas</strong>
<ul>
<li><strong>come to clinical attention at a later stage</strong></li>
<li><strong>Macroadenomas</strong></li>
<li><strong>may cause hypopituitarism</strong></li>
</ul></li>
</ul>
<p><strong>Pituitary Adenomas</strong></p>
<p><img src="img%5CPituitary-Diseases31.png" class="img-fluid"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>
<section id="prolactinomas" class="level1">
<h1>Prolactinomas</h1>
<p><strong>Most common type of hyperfunctioning pituitary adenoma</strong></p>
<p><strong>Range in size from small microadenomas to large, expansile tumors associated with considerable mass effect</strong></p>
<p><strong>Prolactin is demonstrable within the cytoplasm of the neoplastic cells by immunohistochemical techniques</strong></p>
</section>
<section id="hyperprolactinemia" class="level1">
<h1>Hyperprolactinemia</h1>
<ul>
<li><strong>amenorrhea, galactorrhea, loss of libido, and infertility</strong></li>
<li><strong>Diagnosed at an earlier stage in women of reproductive age</strong></li>
<li><strong>May be quite subtle in men and older women</strong>
<ul>
<li><strong>tumor may reach considerable size before coming to clinical attention</strong></li>
</ul></li>
<li><strong>Causes other than prolactin-secreting pituitary adenomas:</strong>
<ul>
<li><strong>pregnancy</strong></li>
<li><strong>high-dose estrogen therapy</strong></li>
<li><strong>renal failure</strong></li>
<li><strong>hypothyroidism</strong></li>
<li><strong>hypothalamic lesions</strong></li>
<li><strong>dopamine-inhibiting drugs (e.g., reserpine)</strong></li>
<li><strong>Stalk effect</strong>
<ul>
<li><strong>Any mass in the suprasellar compartment may disturb the normal inhibitory influence of hypothalamus on prolactin secretion, resulting in hyperprolactinemia</strong></li>
<li><strong>Mild elevations of serum prolactin (less than 200 µg/L) in a patient with a pituitary adenoma do not necessarily indicate a prolactin-secreting neoplasm</strong></li>
</ul></li>
</ul></li>
</ul>
<p><img src="img%5CPituitary-Diseases32.png" class="img-fluid"></p>
<p><strong>Robbins and Cotran Pathologic Basis of Disease</strong></p>
</section>
<section id="growth-hormoneproducing-somatotroph-cell-adenomas" class="level1">
<h1>Growth Hormone–Producing (Somatotroph Cell) Adenomas</h1>
<ul>
<li><p><strong>Second most common type of functional pituitary adenoma</strong></p>
<ul>
<li><strong>GH adenomas</strong></li>
<li><strong>Mixed GH+ PRL adenomas</strong></li>
</ul></li>
<li><p><strong>Clinical manifestations of excessive growth hormone may be subtle</strong></p></li>
<li><p><strong>Somatotroph cell adenomas may be quite large by the time they come to clinical attention</strong></p></li>
<li><p><strong>Composed of densely or sparsely granulated cells</strong></p></li>
<li><p><strong>Immunohistochemical staining demonstrates growth hormone within the cytoplasm of the neoplastic cells</strong></p></li>
<li><p><strong>Small amounts of immunoreactive prolactin often are present as well</strong></p></li>
<li><p><strong>Persistent hypersecretion of growth hormone</strong></p>
<ul>
<li><strong>Stimulates the hepatic secretion of insulin-like growth factor I (somatomedin C)</strong></li>
<li><strong>Causes many of the clinical manifestations</strong></li>
</ul></li>
<li><p><strong>Before the epiphyses close, prepubertal children</strong></p>
<ul>
<li><strong>Gigantism</strong>
<ul>
<li><strong>generalized increase in body size</strong></li>
<li><strong>disproportionately long arms and legs</strong></li>
</ul></li>
</ul></li>
<li><p><strong>After closure of the epiphyses</strong></p>
<ul>
<li><strong>Acromegaly</strong>
<ul>
<li><strong>Growth in soft tissues, skin, and viscera and in the bones of the face, hands, and feet</strong></li>
<li><strong>Prognathism</strong>
<ul>
<li><strong>Enlargement of the jaw results in its protrusion</strong></li>
<li><strong>Broadening of the lower face and separation of the teeth</strong></li>
</ul></li>
<li><strong>Hands and feet are enlarged</strong></li>
<li><strong>Broad, sausage-like fingers</strong></li>
</ul></li>
</ul></li>
<li><p><strong>Growth hormone excess</strong></p>
<ul>
<li><strong>abnormal glucose tolerance</strong></li>
<li><strong>diabetes mellitus</strong></li>
<li><strong>generalized muscle weakness</strong></li>
<li><strong>hypertension</strong></li>
<li><strong>arthritis</strong></li>
<li><strong>osteoporosis</strong></li>
<li><strong>congestive heart failure</strong></li>
</ul></li>
</ul>
</section>
<section id="adrenocorticotropic-hormoneproducing-corticotroph-cell-adenomas" class="level1">
<h1>Adrenocorticotropic Hormone–Producing (Corticotroph Cell) Adenomas</h1>
<ul>
<li><p><strong>Most are small (microadenomas) at the time of diagnosis</strong></p></li>
<li><p><strong>Stain positively with periodic acid–Schiff (PAS) stains</strong></p>
<ul>
<li><strong>accumulation of glycosylated ACTH protein</strong></li>
</ul></li>
<li><p><strong>Secretory granules can be detected by immunohistochemical methods</strong></p></li>
<li><p><strong>Electron microscopy they appear as membrane-bound, electron-dense granules averaging 300 nm in diameter</strong></p></li>
<li><p><strong>May be clinically silent</strong></p></li>
<li><p><strong>May cause hypercortisolism</strong></p>
<ul>
<li><strong>Cushing syndrome</strong></li>
<li><strong>stimulatory effect of ACTH on the adrenal cortex</strong></li>
</ul></li>
<li><p><strong>Cushing disease</strong></p>
<ul>
<li><strong>When the hypercortisolism is caused by excessive production of ACTH by the pituitary</strong></li>
</ul></li>
<li><p><strong>Nelson syndrome</strong></p>
<ul>
<li><strong>Large, clinically aggressive corticotroph cell adenomas may develop after surgical removal of the adrenal glands for treatment of Cushing syndrome</strong></li>
<li><strong>when adrenals removed surgically</strong></li>
<li><strong>loss of the inhibitory effect of adrenal corticosteroids on a preexisting corticotroph microadenoma</strong></li>
<li><strong>patients present with the mass effects of the pituitary tumor</strong></li>
</ul></li>
</ul>
</section>
<section id="gonadotroph-luteinizing-hormone-lhproducing-and-follicle-stimulating-hormone-fshproducing-adenomas" class="level1">
<h1>Gonadotroph (luteinizing hormone <a href="#lh">LH</a>–producing and follicle-stimulating hormone <a href="#fsh">FSH</a>–producing) adenomas</h1>
<p><strong>Difficult to recognize</strong></p>
<p><strong>Secrete hormones inefficiently and variably</strong></p>
<p><strong>Secretory products usually do not cause a recognizable clinical syndrome</strong></p>
<p><strong>Detected with mass effects</strong></p>
<p><strong>Immunoreactivity for the common gonadotropin α-subunit and the specific β-FSH and β-LH subunits; FSH usually is the predominant secreted hormone</strong></p>
</section>
<section id="thyrotroph-thyroid-stimulating-hormone-tshproducing-adenomas" class="level1">
<h1>Thyrotroph (thyroid-stimulating hormone <a href="#tsh">TSH</a>–producing) adenomas</h1>
<p><strong>1% of all pituitary adenomas and constitute a rare cause of hyperthyroidism</strong></p>
</section>
<section id="nonfunctioning-pituitary-adenomas" class="level1">
<h1>Nonfunctioning pituitary adenomas</h1>
<ul>
<li><strong>25% of all pituitary tumors</strong></li>
<li><strong>Characterized by mass effects</strong></li>
<li><strong>Hypopituitarism</strong></li>
<li><strong>Clinically silent counterparts of the functioning adenomas</strong>
<ul>
<li><strong>silent gonadotroph adenoma</strong></li>
</ul></li>
<li><strong>True hormone-negative (null cell) adenomas</strong>
<ul>
<li><strong>infrequent</strong></li>
</ul></li>
</ul>
</section>
<section id="pituitary-carcinomas" class="level1">
<h1>Pituitary carcinomas</h1>
<p><strong>Exceedingly rare</strong></p>
<p><strong>Local extension beyond the sella turcica</strong></p>
<p><strong>Distant metastases</strong></p>
</section>
<section id="hypopituitarism" class="level1">
<h1>Hypopituitarism</h1>
<p><strong>Loss or absence of 75% or more of the anterior pituitary parenchyma</strong></p>
<p><strong>Congenital (exceedingly rare)</strong></p>
<p><strong>Nonfunctioning pituitary adenomas</strong></p>
<ul>
<li><p><strong>Ischemic necrosis of the anterior pituitary</strong></p>
<ul>
<li><strong>Sheehan syndrome</strong>
<ul>
<li><strong>postpartum necrosis of the anterior pituitary</strong></li>
<li><strong>physiologic enlargement of the gland during pregnancy is not accompanied by an increase in blood supply from the low-pressure portal venous system</strong></li>
<li><strong>significant hemorrhage and hypotension during the peripartal period</strong></li>
<li><strong>posterior pituitary is not effected, receives its blood directly from arterial branches</strong></li>
</ul></li>
<li><strong>disseminated intravascular coagulation</strong></li>
<li><strong>sickle cell anemia</strong></li>
<li><strong>elevated intracranial pressure</strong></li>
<li><strong>traumatic injury</strong></li>
<li><strong>shock of any origin</strong></li>
</ul></li>
<li><p><strong>The residual gland is shrunken and scarred</strong></p></li>
<li><p><strong>Ablation of the pituitary by surgery or irradiation</strong></p></li>
<li><p><strong>Inflammatory lesions</strong></p>
<ul>
<li><strong>sarcoidosis or tuberculosis</strong></li>
</ul></li>
<li><p><strong>Trauma</strong></p></li>
<li><p><strong>Metastatic neoplasms involving the pituitary</strong></p></li>
</ul>
</section>
<section id="clinical-manifestations-of-anterior-pituitary-hypofunction" class="level1">
<h1>Clinical manifestations of anterior pituitary hypofunction</h1>
<ul>
<li><strong>Depend on the specific hormones that are lacking</strong></li>
<li><strong>Growth hormone deficiency</strong>
<ul>
<li><strong>Growth failure (pituitary dwarfism)</strong></li>
</ul></li>
<li><strong>Gonadotropin or gonadotropin-releasing hormone (GnRH) deficiency</strong>
<ul>
<li><strong>amenorrhea and infertility in women</strong></li>
<li><strong>decreased libido, impotence, and loss of pubic and axillary hair in men</strong></li>
</ul></li>
<li><strong>TSH</strong>
<ul>
<li><strong>hypothyroidism</strong></li>
</ul></li>
<li><strong>ACTH</strong>
<ul>
<li><strong>hypoadrenalism</strong></li>
</ul></li>
<li><strong>Prolactin deficiency</strong>
<ul>
<li><strong>failure of postpartum lactation</strong></li>
</ul></li>
<li><strong>Loss of stimulatory effects of MSH on melanocytes</strong>
<ul>
<li><strong>Pallor</strong></li>
</ul></li>
</ul>
<p><img src="img%5CPituitary-Diseases33.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases34.jpg" class="img-fluid"></p>
</section>
<section id="posterior-pituitary-syndromes" class="level1">
<h1>POSTERIOR PITUITARY SYNDROMES</h1>
</section>
<section id="posterior-pituitary-syndromes-1" class="level1">
<h1>Posterior Pituitary Syndromes</h1>
<ul>
<li><strong>Neurohypophysis</strong>
<ul>
<li><strong>composed of modified glial cells (termed pituicytes )</strong></li>
<li><strong>Axonal processes extending from nerve cell bodies in the supraoptic and paraventricular nuclei of the hypothalamus</strong></li>
</ul></li>
<li><strong>Hypothalamic neurons produce two peptides</strong>
<ul>
<li><strong>antidiuretic hormone (ADH) and oxytocin</strong></li>
<li><strong>They are stored in axon terminals in the neurohypophysis</strong></li>
<li><strong>Released into the circulation in response to stimuli</strong></li>
</ul></li>
<li><strong>Oxytocin</strong>
<ul>
<li><strong>stimulates the contraction of smooth muscle in the pregnant uterus</strong></li>
<li><strong>muscle surrounding the lactiferous ducts of the mammary glands</strong></li>
<li><strong>Impairment of oxytocin synthesis and release has not been associated with significant clinical abnormalities</strong></li>
</ul></li>
<li><strong>ADH</strong>
<ul>
<li><strong>diabetes insipidus</strong></li>
<li><strong>secretion of inappropriately high levels of ADH</strong></li>
</ul></li>
</ul>
</section>
<section id="antidiuretic-hormone" class="level1">
<h1>Antidiuretic hormone</h1>
<ul>
<li><strong>Synthesized predominantly in the supraoptic nucleus</strong></li>
<li><strong>ADH is released in response to</strong>
<ul>
<li><strong>Increased plasma oncotic pressure, left atrial distention, exercise, and certain emotional states</strong></li>
<li><strong>acts on the collecting tubules of the kidney to promote the resorption of free water</strong></li>
</ul></li>
<li><strong>ADH deficiency causes diabetes insipidus</strong>
<ul>
<li><p><strong>excessive urination (polyuria)</strong></p></li>
<li><p><strong>inability of the kidney to properly resorb water from the urine</strong></p></li>
<li><p><strong>Syndrome of inappropriate ADH (SIADH) secretion</strong></p>
<ul>
<li><strong>Resorption of excessive amounts of free water</strong></li>
<li><strong>Hyponatremia, cerebral edema, neurologic dysfunction</strong></li>
</ul></li>
<li><p><strong>ADH excess is caused by several extracranial and intracranial disorders</strong></p>
<ul>
<li><strong>secretion of ectopic ADH by malignant neoplasms</strong>
<ul>
<li><strong>small cell carcinomas of the lung</strong></li>
</ul></li>
<li><strong>non-neoplastic diseases of the lung</strong></li>
<li><strong>Local injury to the hypothalamus or neurohypophysis</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="hypothalamic-suprasellar-tumors" class="level1">
<h1>HYPOTHALAMIC SUPRASELLAR TUMORS</h1>
<p><img src="img%5CPituitary-Diseases35.png" class="img-fluid"></p>
<p><strong>Craniopharyngioma</strong></p>
<p><strong>Autopsy Pathology: A Manual and Atlas</strong></p>
</section>
<section id="craniopharyngioma" class="level1">
<h1>Craniopharyngioma</h1>
<ul>
<li><p><strong>Arise from vestigial remnants of Rathke pouch</strong></p></li>
<li><p><strong>1-5% of intracranial tumors</strong></p></li>
<li><p><strong>Most are suprasellar, with or without intrasellar extension</strong></p></li>
<li><p><strong>Bimodal age distribution</strong></p>
<ul>
<li><strong>one peak in childhood (5 to 15 years)</strong></li>
<li><strong>second peak in adults 65 years or older</strong></li>
</ul></li>
<li><p><strong>Abnormalities of the WNT signaling pathway, mutations of β-catenin</strong></p></li>
<li><p><strong>Average 3-4 cm in diameter</strong></p></li>
<li><p><strong>Cystic and sometimes multiloculated</strong></p></li>
<li><p><strong>Adamantinomatous craniopharyngioma</strong></p>
<ul>
<li><strong>Children</strong></li>
<li><strong>Calcifications</strong></li>
<li><strong>cysts of adamantinomatous craniopharyngiomas often contain a cholesterol-rich, thick brownish-yellow fluid, “machine oil”</strong></li>
</ul></li>
<li><p><strong>Papillary craniopharyngioma</strong></p>
<ul>
<li><strong>most often observed in adults</strong></li>
</ul></li>
</ul>
<p><img src="img%5CPituitary-Diseases36.png" class="img-fluid"></p>
<p><strong>Robbins and Cotran Pathologic Basis of Disease</strong></p>
</section>
<section id="section" class="level1">
<h1></h1>
<p><img src="img%5CPituitary-Diseases37.png" class="img-fluid"></p>
</section>
<section id="hipofiz-adenomuna-yaklaşım" class="level1">
<h1>Hipofiz adenomuna yaklaşım</h1>
</section>
<section id="dr.-serdar-balcı" class="level1">
<h1>Dr.&nbsp;Serdar Balcı</h1>
</section>
<section id="klinik-bilgi" class="level1">
<h1>Klinik bilgi</h1>
<ul>
<li><strong>Çocuklarda: PRL, ACTH</strong></li>
<li><strong>Hormon düzeylerinde artış</strong>
<ul>
<li><strong>Hiperprolaktinemi → nonspesifik</strong></li>
</ul></li>
<li><strong>Kitle etkisi</strong>
<ul>
<li><strong>Başağrısı</strong></li>
<li><strong>Görme alanı</strong></li>
<li><strong>Hipopituitarism</strong></li>
</ul></li>
<li><strong>D. insipid ve kraniel sinir arazı</strong>
<ul>
<li><strong>Öncelikle diğer tümörler, metastazlar</strong></li>
<li><strong>İnflamatuar süreçler</strong></li>
</ul></li>
</ul>
</section>
<section id="ameliyat" class="level1">
<h1>Ameliyat</h1>
<p><strong>Eğer hemen patolojiye gelecekse SF içeren tüpte gönderilebilir. (Otoliz, formolsüz diye not konan rapor sayısı)</strong></p>
<p><strong>Gazlı bezi unutun</strong></p>
<p><strong>Formaldehit</strong></p>
<p><strong>EM inceleme?</strong></p>
</section>
<section id="hipofiz-adenomu---frozen" class="level1">
<h1>Hipofiz adenomu - Frozen</h1>
<ul>
<li><strong>Doku genelde küçük</strong>
<ul>
<li><strong>Donma artefaktı</strong></li>
</ul></li>
<li><strong>Yayma</strong>
<ul>
<li><strong>Daha az doku yeterli</strong></li>
<li><strong>Deneyim gerektiriyor</strong></li>
</ul></li>
<li><strong>Tek tanısal materyal frozenda </strong> <em>harcanmış </em> <strong>olabilir</strong></li>
<li><strong>Frozen beklenmedik bir bulgu ile karşılaşınca uygulanabilir (başka tümör şüphesi)</strong></li>
<li><strong>İntraoperatif retikülin?</strong></li>
<li><strong>Cerrahi sınır?</strong></li>
</ul>
</section>
<section id="mikroadenom-frozen" class="level1">
<h1>Mikroadenom – Frozen?</h1>
</section>
<section id="adenohipofiz" class="level1">
<h1>Adenohipofiz</h1>
<p><strong>Lobüler yapı</strong></p>
<p><strong>Coğrafi dağılım</strong></p>
<p><strong>Tükrük bezi benzeri bezler gibi taklitçiler</strong></p>
</section>
<section id="ara-lob" class="level1">
<h1>Ara lob???</h1>
</section>
<section id="nörohipofiz" class="level1">
<h1>Nörohipofiz</h1>
</section>
<section id="suprasellar-kitleler---ddx" class="level1">
<h1>Suprasellar kitleler - Ddx</h1>
<p><strong>Pituisitom</strong></p>
<p><strong>Lenfositik/granülamatöz hipofizit</strong></p>
<p><strong>Lenfoma</strong></p>
<p><strong>Gangliositom/Gangliositoadenom</strong></p>
<p><strong>Germ hücreli tümörler</strong></p>
<p><strong>Granüler hücrrli tümör</strong></p>
<p><strong>Plazmasitom</strong></p>
<p><strong>Lenfoma</strong></p>
<p><strong>Paragangliom</strong></p>
<p><strong>Metastaz</strong></p>
<p><img src="img%5CPituitary-Diseases38.png" class="img-fluid"></p>
</section>
<section id="section-1" class="level1">
<h1></h1>
<p><img src="img%5CPituitary-Diseases39.png" class="img-fluid"></p>
</section>
<section id="sellar-kitleler" class="level1">
<h1>Sellar kitleler</h1>
<p><strong>Kraniyofarengiom</strong></p>
<p><strong>Rathke kleft kisti</strong></p>
<p><strong>Teratom</strong></p>
<p><strong>Kordoma</strong></p>
<p><strong>Germinom</strong></p>
<p><strong>Pilositik astrositom</strong></p>
<p><strong>Lenfoma</strong></p>
<p><strong>İnflamasyon</strong></p>
<p><strong>Langerhans hücreli histiyositoz</strong></p>
<p><strong>Granüler hücreli tümör</strong></p>
<p><strong>Glezer et al, Rare Sellar Lesions, Endocrinol Metab Clin N Am 37 (2008) 195–211</strong></p>
<p><img src="img%5CPituitary-Diseases40.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases41.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases42.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases43.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases44.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases45.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases46.jpg" class="img-fluid"></p>
</section>
<section id="section-2" class="level1">
<h1></h1>
<p><strong>Postmortem prevalence of pituitary adenoma is 14.4% </strong></p>
<p><strong>radiologic studies identify a lesion consistent with pituitary adenoma in 22.2% of the population</strong></p>
<p><strong>providing an overall estimated prevalence of 16.9%.</strong></p>
</section>
<section id="adenom---hiperplazi" class="level1">
<h1>Adenom - Hiperplazi</h1>
<ul>
<li><strong>Diffüz, nodüler</strong></li>
<li><strong>Hiperplazi</strong>
<ul>
<li><strong>Stimulus kesilince büyüme durur</strong></li>
<li><strong>Gebelik: laktotrop hücre proliferasyonu</strong></li>
<li><strong>Primer hipopituitarizm: tirotrop</strong></li>
<li><strong>Hipotalamik gangliositom, GHrH eksprese eden tümörler: somatotrop</strong></li>
<li>__ CrH: bronşial, gastroenterohepatik, adrenal, prostat endokrin tümörler__</li>
</ul></li>
</ul>
<p><img src="img%5CPituitary-Diseases47.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases48.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases49.png" class="img-fluid"></p>
</section>
<section id="hipofiz-adenomu" class="level1">
<h1>Hipofiz adenomu</h1>
</section>
<section id="ffpe-he" class="level1">
<h1>FFPE – H&amp;E</h1>
<ul>
<li><strong>H&amp;E</strong></li>
<li><strong>10 boyasız</strong>
<ul>
<li><strong>Retikülin</strong></li>
<li><strong>PAS?</strong></li>
<li><strong>MIB-1</strong></li>
<li><strong>p53</strong></li>
<li><strong>Hormonlar</strong></li>
</ul></li>
</ul>
<p><strong>Nükleus</strong></p>
<p><strong>Nükleol</strong></p>
<p><strong>Kromatin</strong></p>
<p><strong>Atipi?</strong></p>
<p><strong>Mitoz</strong></p>
<p><strong>Sitoplazma</strong></p>
<p><strong>Yapı</strong></p>
<p><strong>Papiller</strong></p>
<p><strong>Amiloid</strong></p>
<p><strong>Kalsifikasyon</strong></p>
<p><strong>Tedavi etkisi</strong></p>
</section>
<section id="retikülin-adenohipofiz-hiperplazi-adenom" class="level1">
<h1>Retikülin: Adenohipofiz, Hiperplazi, Adenom</h1>
</section>
<section id="hormon-belirteçleri" class="level1">
<h1>Hormon belirteçleri</h1>
</section>
<section id="gh" class="level1">
<h1>GH</h1>
</section>
<section id="gh-ck8" class="level1">
<h1>GH – CK8</h1>
</section>
<section id="prolaktin" class="level1">
<h1>Prolaktin</h1>
</section>
<section id="prolaktin-ck8" class="level1">
<h1>Prolaktin – CK8</h1>
</section>
<section id="tsh" class="level1">
<h1>TSH</h1>
</section>
<section id="fsh" class="level1">
<h1>FSH</h1>
</section>
<section id="lh" class="level1">
<h1>LH</h1>
</section>
<section id="acth" class="level1">
<h1>ACTH</h1>
</section>
<section id="acth---mikroadenom" class="level1">
<h1>ACTH - mikroadenom</h1>
<p><strong>Retikülin ve ACTH IHK’sı gerekli</strong></p>
<p><strong>Yoğun granüllü</strong></p>
<p><strong>Bazofilik hücreler</strong></p>
<p><strong>PAS +</strong></p>
<p><strong>CAM 5.2, CK7, CK8</strong></p>
</section>
<section id="acth--crooke-değişiklik" class="level1">
<h1>ACTH- Crooke değişiklik</h1>
<ul>
<li><strong>Tümörsüz alanda (genellikle kortikotroplarda)</strong></li>
<li><strong>Dolaşımdaki artmış glukokortikoid varlığını yansıtır</strong>
<ul>
<li><strong>Pituiter kortikotrop adenom</strong></li>
<li><strong>Ektopik ACTH sekresyonu</strong></li>
<li><strong>Primer adrenal patolojiler</strong></li>
<li><strong>İatrojenik</strong></li>
</ul></li>
<li><strong>Adenom görülmediyse mikroadenom varlığı araştırılmalı (1-2 mm’lik seri kesitler, retikülin ve ACTH ile bakılarak)</strong></li>
<li><strong>Adenom görülmezse klinikopatolojik korelasyon gerektirir</strong></li>
</ul>
<p><img src="img%5CPituitary-Diseases50.png" class="img-fluid"></p>
</section>
<section id="acth--crooke-cell" class="level1">
<h1>ACTH- Crooke cell</h1>
<ul>
<li><strong>Adenom görülmediyse mikroadenom varlığı araştırılmalı</strong>
<ul>
<li><strong>1-2 mm’lik seri kesitler</strong></li>
<li><strong>Retikülin ve ACTH ile bakılarak</strong></li>
</ul></li>
<li><strong>Adenom görülmezse klinikopatolojik korelasyon gerektirir</strong>
<ul>
<li><strong>Hâlâ sellada adenom var mı?</strong></li>
<li><strong>Kortikoid yüksekliğinin başka nedenleri</strong></li>
<li><strong>Aspiratörde ya da seri kesitlerde kaybolan adenom?</strong></li>
</ul></li>
</ul>
</section>
<section id="acth-crooke-değişiklik-yok-adenom-yok" class="level1">
<h1>ACTH Crooke değişiklik yok, adenom yok</h1>
<ul>
<li><strong>Kortikotrop hiperplazi?</strong>
<ul>
<li><strong>Patolojik değerlendirme zor olabilir</strong></li>
</ul></li>
<li><strong>Psödo Cushing</strong></li>
</ul>
</section>
<section id="acth-crooke-cell-adenoma" class="level1">
<h1>ACTH – Crooke cell adenoma</h1>
<p><strong>Adenomatöz hücrelerin sitoplazmasında yoğun birikim</strong></p>
<p><strong>Nükleer pleomorfizm, iri hücre</strong></p>
<p><strong>DDX: gangliositom, metastaz</strong></p>
<p><strong>ACTH +</strong></p>
<p><strong>Yoğun halka şeklinde keratin birikimi</strong></p>
<p><strong>CAM 5.2 +</strong></p>
</section>
<section id="p53" class="level1">
<h1>p53</h1>
</section>
<section id="ki-67" class="level1">
<h1>Ki-67</h1>
</section>
<section id="pit-1" class="level1">
<h1>Pit-1</h1>
</section>
<section id="er-α" class="level1">
<h1>ER-α</h1>
</section>
<section id="mukozada-ekilim" class="level1">
<h1>Mukozada ekilim?</h1>
</section>
<section id="serum-ihk-korelasyonu" class="level1">
<h1>Serum – IHK korelasyonu</h1>
</section>
<section id="otopside-inceleme" class="level1">
<h1>Otopside inceleme</h1>
<p><strong>Stalk yüksekten kesilmeli</strong></p>
<p><strong>Sella kontrol edilmeli</strong></p>
<p><strong>Dorsum sella dan açılarak intakt çıkartılmaya çalışılmalı</strong></p>
<p><img src="img%5CPituitary-Diseases51.png" class="img-fluid"></p>
</section>
<section id="alıntı-slaytlar" class="level1">
<h1>Alıntı slaytlar</h1>
</section>
<section id="section-3" class="level1">
<h1></h1>
</section>
<section id="adenohipofiz-1" class="level1">
<h1>Adenohipofiz</h1>
<p><strong>Lateral kanat</strong></p>
<p><strong>Mukoid wedge</strong></p>
<p><img src="img%5CPituitary-Diseases52.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases53.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases54.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases55.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases56.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases57.png" class="img-fluid"></p>
</section>
<section id="hipofiz-adenomu-sınıflandırması" class="level1">
<h1>Hipofiz adenomu sınıflandırması</h1>
<p><strong>Cerrahi, radyoloji</strong></p>
<ul>
<li><strong>İnvazif</strong>
<ul>
<li><strong>Dura</strong></li>
<li><strong>Kemik</strong></li>
<li><strong>Sinüsler</strong></li>
</ul></li>
<li><strong>Non-invazif</strong></li>
</ul>
<p><strong>Hormon aktif</strong></p>
<p><strong>Nonfonksiyone</strong></p>
<p><strong>Mikroadenom &lt;1cm</strong></p>
<p><strong>Makroadenom &gt;1cm</strong></p>
<p><img src="img%5CPituitary-Diseases58.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases59.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases60.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases61.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases62.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases63.jpg" class="img-fluid"></p>
</section>
<section id="büyüme-hormonu-adenomu" class="level1">
<h1>Büyüme Hormonu Adenomu</h1>
<p><strong>%10</strong></p>
<p><strong>%25-30</strong></p>
<p><strong>Gigantizm, akromegali</strong></p>
<p><strong>İnvaziv makroadenom</strong></p>
<p><strong>IGF-1</strong></p>
</section>
<section id="yoğun-granüllü-gh-adenomu" class="level1">
<h1>Yoğun granüllü GH adenomu</h1>
<p><strong>Yuvarlak, polihedral, asidofilik</strong></p>
<p><strong>Yaygın, kuvvetli sitoplazmik GH</strong></p>
<p><strong>Perinükleer CK8</strong></p>
<p><strong>Yarısında α-subünit pozitif</strong></p>
<p><strong>Pit-1 kuvvetli nükleer pozitif</strong></p>
<p><strong>EM sekretuvar granüller bol</strong></p>
</section>
<section id="seyrek-granüllü-gh-adenomu" class="level1">
<h1>Seyrek granüllü GH adenomu</h1>
<ul>
<li><p><strong>Küçük, yuvarlak, kısmen düzensiz hücreler</strong></p></li>
<li><p><strong>Fibröz cisimler</strong></p>
<ul>
<li><strong>Paranükleer soluk asidofilik küresel inklüzyon</strong></li>
<li><strong>LMWCK, CK8 pozitif</strong></li>
</ul></li>
<li><p><strong>Pleomorfizm, çok çekirdekli bizar hücreler</strong></p></li>
<li><p><strong>GH zayıf sitoplazmik</strong></p></li>
<li><p><strong>Pit-1 kuvvetli nükleer pozitif</strong></p></li>
<li><p><strong>Daha agresif</strong></p></li>
<li><p><strong>Multinükleer, pleomorfizm</strong></p>
<ul>
<li><strong>Prognostik değil</strong></li>
</ul></li>
<li><p><strong>Makroadenom, invazif</strong></p></li>
<li><p><strong>Otokrin</strong></p>
<ul>
<li><strong>GHrH salgılıyor</strong></li>
</ul></li>
</ul>
</section>
<section id="prl-hücre-adenomu" class="level1">
<h1>PRL hücre adenomu</h1>
<ul>
<li><strong>%25-30</strong></li>
<li><strong>Serum PRL düzeyi genelde tümör boyutu ile paralel</strong>
<ul>
<li><strong>&gt;150ng/mL tanısal</strong></li>
<li><strong>Daha düşük değerler bası etkisini yansıtır</strong></li>
</ul></li>
<li><strong>Kadınlarda mikroadenom şeklinde</strong>
<ul>
<li><strong>Galaktore, amenore</strong></li>
</ul></li>
<li><strong>Erkeklerde</strong>
<ul>
<li><strong>Libido azalması, impotans</strong></li>
</ul></li>
<li><strong>Mikroadenom lateral ve posteriorda</strong></li>
<li><strong>Genelde diffüz, nadiren papiller</strong></li>
<li><strong>Nadir iri, uzun hücreler, belirgin membran</strong></li>
</ul>
<p><strong>Amiloid depolanması, kalsifikasyon</strong></p>
<p><strong>Pitüiter taş</strong></p>
</section>
<section id="seyrek-granüllü-laktotrop-adenomu" class="level1">
<h1>Seyrek granüllü laktotrop adenomu</h1>
<ul>
<li><strong>Kromofob, amfofilik</strong>
<ul>
<li><strong>Belirgin </strong> <em>rough</em> __ endoplazmik retikulum içerir__</li>
</ul></li>
<li><strong>Paranükleer (golgi) paterninde PRL pozitif</strong></li>
<li><strong>Pit-1 nükleer kuvvetli</strong></li>
</ul>
</section>
<section id="yoğun-granüllü-laktotrop-adenomu" class="level1">
<h1>Yoğun granüllü laktotrop adenomu</h1>
<p><strong>Nadir</strong></p>
</section>
<section id="dopamin-agonisti-tedavisi-etkisi" class="level1">
<h1>Dopamin agonisti tedavisi etkisi</h1>
<p><strong>Atrofi</strong></p>
<p><strong>Hücre boyutunda küçülme</strong></p>
<p><strong>Sitoplazmada büzüşme</strong></p>
<p><strong>N/C oranında artma</strong></p>
<p><strong>İnterstisyel ve perivasküler fibrozis</strong></p>
</section>
<section id="tsh-hücre-adenomu" class="level1">
<h1>TSH hücre adenomu</h1>
<p><strong>Nadir</strong></p>
<p><strong>İnvaziv</strong></p>
<p><strong>Solid, sinüzoidal patern</strong></p>
<p><strong>Stromal fibrozis, psammom cisimleri</strong></p>
<p><strong>Hücre sınırları belirsiz kromofob adenom</strong></p>
<p><strong>Nükleer pleomorfizm olabilir</strong></p>
<p><strong>PAS sitoplazmik granüller</strong></p>
<p><strong>Sitoplazma: α-subünit, β-TSH</strong></p>
<p><strong>Nükleer Pit-1</strong></p>
<p><strong>Plurihormonal ekspresyon izlenebilir</strong></p>
</section>
<section id="acth-hücre-adenomu" class="level1">
<h1>ACTH hücre adenomu</h1>
<ul>
<li><strong>%10-15</strong></li>
<li><strong>Makroskopik: kırmızı ve yumuşak mikroadenom</strong></li>
<li><strong>Seri kesitlere rağmen izlenemeyebilir</strong></li>
<li><strong>Nadir kavernöz sinüs invazyonu</strong>
<ul>
<li><strong>Klinik ve biyokimyasal semptom yok</strong></li>
<li><strong>Sessiz</strong></li>
</ul></li>
</ul>
<p><strong>Diffüz, sinüzoidal</strong></p>
<p><strong>Bazofilik, amfofilik, monomorfik, yuvarlak</strong></p>
<p><strong>Kuvvetli PAS pozitif</strong></p>
<p><strong>Crooke hyalen değişim</strong></p>
<p><strong>Pleomorfizm</strong></p>
<p><strong>Mitoz nadir</strong></p>
<p><strong>ACTH, β-LPH ve/veya β-endorfin</strong></p>
<p><strong>Cushing hastalığı (pitüiter ACTH fazlalığı)</strong></p>
<p><strong>Nelson zemininde gelişen</strong></p>
<p><strong>Crooke cell adenoma</strong></p>
<p><strong>Sessiz kortikotrop adenomlar</strong></p>
</section>
<section id="cushing-hastalığı-pitüiter-acth-fazlalığı" class="level1">
<h1>Cushing hastalığı (pitüiter ACTH fazlalığı)</h1>
</section>
<section id="gonadotrop-hücre-adenomu" class="level1">
<h1>Gonadotrop hücre adenomu</h1>
<p><strong>Nadir?</strong></p>
<p><strong>Fonksiyonel olanlar erkeklerde daha sık</strong></p>
<p><strong>Sessiz adenomlarda IHK ile tanı konur</strong></p>
<p><strong>Makroadenom</strong></p>
<p><strong>Supra, parasellar</strong></p>
<p><strong>Sinüzoid, psödorozet</strong></p>
<p><strong>Kanama, nekroz olabilir</strong></p>
<p><strong>PAS negatif, onkositik olabilir</strong></p>
<p><strong>α-subünit, β-FSH (daha sık), β-LH pozitif</strong></p>
</section>
<section id="plurihormonal-adenomlar" class="level1">
<h1>Plurihormonal Adenomlar</h1>
<ul>
<li><strong>Pit-1</strong>
<ul>
<li><strong>Karışık somatotrop-laktotrop</strong>
<ul>
<li><strong>Akromegali, stalka bası</strong></li>
<li><strong>İki farklı hücre tipi</strong></li>
</ul></li>
<li><strong>Mammosomatotrop</strong>
<ul>
<li><strong>Klinik sakin, akromegali, hiperPRL</strong></li>
<li><strong>Aynı hücrede GH ve PRL</strong></li>
</ul></li>
<li><strong>Asidofil kök hücre</strong>
<ul>
<li><strong>Klinik sakin veya hiperPRL</strong></li>
<li><strong>Kromofob</strong></li>
<li><strong>İnvaziv</strong></li>
<li><strong>Paranükleer vakuol</strong></li>
<li><strong>Agresif seyir</strong></li>
</ul></li>
<li><strong>Plurihormonal GH üreten adenomlar</strong>
<ul>
<li><strong>Yoğun granüllü GH adenomu</strong></li>
<li><strong>PRL, α-subünit, β-TSH, β-FSH, β-LH</strong></li>
</ul></li>
</ul></li>
<li><strong>ACTH-α subünit</strong></li>
<li><strong>LH/FSH-PRL-β-endorfin</strong></li>
<li><strong>GH-ACTH</strong></li>
<li><strong>PRL-TSH</strong></li>
</ul>
</section>
<section id="null-hücre-adenomu" class="level1">
<h1>Null Hücre Adenomu</h1>
<p><strong>%20, giderek düşüyor</strong></p>
<p><strong>Suprasellar, parasellar invazyon</strong></p>
<p><strong>Kavitasyon, kanama</strong></p>
<p><strong>Yuvarlak, poligonal, kromofob</strong></p>
<p><strong>Diffüz, papiller</strong></p>
<p><strong>Pleomorfizm, mitoz nadir</strong></p>
</section>
<section id="invaziv" class="level1">
<h1>İnvaziv</h1>
<p><strong>Kemik</strong></p>
<p><strong>Kavernöz sinüs</strong></p>
<p><strong>Nazofarenks</strong></p>
<p><strong>Dura</strong></p>
<ul>
<li><strong>Agresif davranış</strong>
<ul>
<li><strong>Rekürrens</strong></li>
<li><strong>Hormon düzeyi normale dönmez</strong></li>
</ul></li>
<li><strong>Dura invazyonu sık</strong>
<ul>
<li><strong>Agresif değil</strong></li>
</ul></li>
</ul>
</section>
<section id="atipik-adenom" class="level1">
<h1>Atipik adenom</h1>
<ul>
<li><strong>Biyolojik</strong>
<ul>
<li><strong>Agresif davranış</strong></li>
<li><strong>Rekürrens</strong></li>
</ul></li>
<li><strong>Ki-67&gt;%3</strong></li>
<li><strong>p53 pozitif</strong></li>
<li><strong>Metastaz yaparlar mı?</strong></li>
</ul>
</section>
<section id="hipofiz-karsinomu" class="level1">
<h1>Hipofiz karsinomu</h1>
<ul>
<li><strong>BOS ya da sistemik yayılımla tanı konur</strong></li>
<li><strong>Erişkinlerde</strong></li>
<li><strong>Nadir</strong></li>
<li><strong>PRL, GH</strong></li>
<li><strong>ACTH olanlar Nelson zemininde</strong></li>
<li><strong>İnvazyon, pleomorfizm, mitoz ve nekroz izlenir</strong>
<ul>
<li><strong>Ancak tanısal ya da prediktif değildir</strong></li>
</ul></li>
</ul>
</section>
<section id="cadillac-approach" class="level1">
<h1>Cadillac approach</h1>
<p><strong>Acta Neuropathol (2006) 111: 68–70</strong></p>
</section>
<section id="section-4" class="level1">
<h1></h1>
<p><img src="img%5CPituitary-Diseases64.png" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases65.png" class="img-fluid"></p>
</section>
<section id="hipofiz-adenomu-1" class="level1">
<h1>Hipofiz adenomu</h1>
</section>
<section id="dialar" class="level1">
<h1>dialar</h1>
<p><img src="img%5CPituitary-Diseases66.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases67.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases68.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases69.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases70.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases71.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases72.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases73.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases74.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases75.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases76.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases77.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases78.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases79.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases80.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases81.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases82.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases83.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases84.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases85.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases86.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases87.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases88.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases89.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases90.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases91.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases92.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases93.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases94.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases95.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases96.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases97.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases98.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases99.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases100.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases101.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases102.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases103.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases104.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases105.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases106.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases107.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases108.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases109.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases110.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases111.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases112.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases113.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases114.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases115.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases116.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases117.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases118.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases119.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases120.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases121.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases122.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases123.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases124.jpg" class="img-fluid"></p>
<p><img src="img%5CPituitary-Diseases125.jpg" class="img-fluid"></p>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const isCodeAnnotation = (el) => {
    for (const clz of el.classList) {
      if (clz.startsWith('code-annotation-')) {                     
        return true;
      }
    }
    return false;
  }
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    text: function(trigger) {
      const codeEl = trigger.previousElementSibling.cloneNode(true);
      for (const childEl of codeEl.children) {
        if (isCodeAnnotation(childEl)) {
          childEl.remove();
        }
      }
      return codeEl.innerText;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
      let selectedAnnoteEl;
      const selectorForAnnotation = ( cell, annotation) => {
        let cellAttr = 'data-code-cell="' + cell + '"';
        let lineAttr = 'data-code-annotation="' +  annotation + '"';
        const selector = 'span[' + cellAttr + '][' + lineAttr + ']';
        return selector;
      }
      const selectCodeLines = (annoteEl) => {
        const doc = window.document;
        const targetCell = annoteEl.getAttribute("data-target-cell");
        const targetAnnotation = annoteEl.getAttribute("data-target-annotation");
        const annoteSpan = window.document.querySelector(selectorForAnnotation(targetCell, targetAnnotation));
        const lines = annoteSpan.getAttribute("data-code-lines").split(",");
        const lineIds = lines.map((line) => {
          return targetCell + "-" + line;
        })
        let top = null;
        let height = null;
        let parent = null;
        if (lineIds.length > 0) {
            //compute the position of the single el (top and bottom and make a div)
            const el = window.document.getElementById(lineIds[0]);
            top = el.offsetTop;
            height = el.offsetHeight;
            parent = el.parentElement.parentElement;
          if (lineIds.length > 1) {
            const lastEl = window.document.getElementById(lineIds[lineIds.length - 1]);
            const bottom = lastEl.offsetTop + lastEl.offsetHeight;
            height = bottom - top;
          }
          if (top !== null && height !== null && parent !== null) {
            // cook up a div (if necessary) and position it 
            let div = window.document.getElementById("code-annotation-line-highlight");
            if (div === null) {
              div = window.document.createElement("div");
              div.setAttribute("id", "code-annotation-line-highlight");
              div.style.position = 'absolute';
              parent.appendChild(div);
            }
            div.style.top = top - 2 + "px";
            div.style.height = height + 4 + "px";
            let gutterDiv = window.document.getElementById("code-annotation-line-highlight-gutter");
            if (gutterDiv === null) {
              gutterDiv = window.document.createElement("div");
              gutterDiv.setAttribute("id", "code-annotation-line-highlight-gutter");
              gutterDiv.style.position = 'absolute';
              const codeCell = window.document.getElementById(targetCell);
              const gutter = codeCell.querySelector('.code-annotation-gutter');
              gutter.appendChild(gutterDiv);
            }
            gutterDiv.style.top = top - 2 + "px";
            gutterDiv.style.height = height + 4 + "px";
          }
          selectedAnnoteEl = annoteEl;
        }
      };
      const unselectCodeLines = () => {
        const elementsIds = ["code-annotation-line-highlight", "code-annotation-line-highlight-gutter"];
        elementsIds.forEach((elId) => {
          const div = window.document.getElementById(elId);
          if (div) {
            div.remove();
          }
        });
        selectedAnnoteEl = undefined;
      };
      // Attach click handler to the DT
      const annoteDls = window.document.querySelectorAll('dt[data-target-cell]');
      for (const annoteDlNode of annoteDls) {
        annoteDlNode.addEventListener('click', (event) => {
          const clickedEl = event.target;
          if (clickedEl !== selectedAnnoteEl) {
            unselectCodeLines();
            const activeEl = window.document.querySelector('dt[data-target-cell].code-annotation-active');
            if (activeEl) {
              activeEl.classList.remove('code-annotation-active');
            }
            selectCodeLines(clickedEl);
            clickedEl.classList.add('code-annotation-active');
          } else {
            // Unselect the line
            unselectCodeLines();
            clickedEl.classList.remove('code-annotation-active');
          }
        });
      }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>